Regenacy Revenue and Competitors
Estimated Revenue & Valuation
- Regenacy's estimated annual revenue is currently $1.7M per year.
- Regenacy's estimated revenue per employee is $155,000
Employee Data
- Regenacy has 11 Employees.
- Regenacy grew their employee count by -15% last year.
Regenacy's People
Name | Title | Email/Phone |
---|---|---|
1 | VP Regulatory Affairs | Reveal Email/Phone |
2 | Chief Financial Officer | Reveal Email/Phone |
3 | President and CEO | Reveal Email/Phone |
Regenacy Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Regenacy?
Regenacy Pharmaceuticals is developing a novel, disease-modifying approach to treating peripheral neuropathies that goes beyond pain and symptom management to restore peripheral nerve function. Our lead compound ricolinostat (ACY-1215) is an oral, selective inhibitor of the microtubule modifying enzyme HDAC6 with first-in-class potential, currently positioned to enter Phase 2 clinical trials. Our investigation of ricolinostat for diabetic, chemotherapy-induced and inherited peripheral neuropathies is based on compelling proof-of-concept preclinical studies demonstrating restoration of normal nerve function. We were founded in December 2016 following the acquisition of Acetylon Pharmaceuticals by Celgene. Regenacy received exclusive rights to ricolinostat, a clinical stage, orally bioavailable, HDAC6 selective inhibitor, for a range of non-cancer disease indications. We also have a unique and proprietary portfolio of selective HDAC1,2 inhibitors with potential for treating cancer, hemoglobinopathies, and cognitive dysfunction.
keywords:N/AN/A
Total Funding
11
Number of Employees
$1.7M
Revenue (est)
-15%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Regenacy News
... Treatment Market Benefit and Volume 2022 with Status and Prospect to 2028 | Aptinyx Inc., Regenacy Pharmaceuticals, MAKScientific LLC.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1M | 11 | 10% | N/A |
#2 | $1.7M | 11 | 0% | N/A |
#3 | $1.6M | 12 | N/A | N/A |
#4 | $1.9M | 12 | 33% | N/A |
#5 | $1.6M | 12 | -14% | N/A |